Global biopharmaceutical market report (2010 2015)

About IMARC
For more than 5 years, the International Market Analysis Research and Consulting Group has been a
leading advisor on management strategy and market research worldwide. We partner with clients in
all sectors and regions to identify their highest-value opportunities, address their most critical
challenges, and transform their businesses.
IMARC's information products include major market, scientific, economic and technological
developments for business leaders in pharmaceutical, industrial, and high technology organizations.
Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food
and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of
the company's expertise.
IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and
markets with close cooperation at all levels of the client organization. This ensures that our clients
achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting
results.

© IMARC®
Report Description & Highlights
The Global Biopharmaceutical Industry has come a long way since its first drug- Humulin was approved in
1982. Today more than three hundred biopharmaceuticals have already been approved and many more are
in late stage clinical development. These drugs have not only advanced the prevention and treatment of a
number of life threatening diseases, but have also provided the thrust for the continued success of the
pharmaceutical industry.
Under mounting economic pressures to increase their outputs, pharmaceutical manufacturers have
embraced biopharmaceuticals as a means to maintain flow in their drying pipelines. Bringing a
biopharmaceutical, however, represents a very risky proposition and out of every ten drugs that enter the
clinical phases, only three manage to gain market approval. But the industry’s US$ 92 Billion figures and
double digit growth rates in the last five years are a testimonial to the fact that the ones that finally do get
approval represent goldmines for investors.
Although factors such as biosimilar entry and cost containment in the developed markets are likely to
restrain the growth of this market in the coming years, Imarc expects that the high potency and ability of
biopharmaceuticals to attack targets beyond the reach of traditional small molecule drugs gives the industry
a huge scope for future growth. A rich late stage pipeline and the growth of emerging markets are also
expected to be major drivers for growth in the next five years. IMARC expects the global biopharmaceutical
market to reach level of sales figures worth more than US$ 167 Billion by 2015.
IMARC’s new report “Global Biopharmaceutical Market Report (2010-2015)” gives a deep insight into the
global biopharmaceutical market. The research study serves as an analytical as well as a statistical tool to
understand the strengths, weaknesses, opportunities, threats, market trends, geographical structure,
therapeutic structure, competitive structure and the outlook of the global biopharmaceutical market till
2015. This report can serve as an excellent guide for investors, researchers, consultants, marketing
strategists, and all those who are planning to foray into the global biopharmaceutical market in some form
or the other.
Report Highlights
Biopharmaceuticals enjoy a higher approval success rate compared to traditional small molecule
drugs. They, however, require higher investments and take longer development times.
Biopharmaceuticals are significantly more expensive than traditional medications, with the annual
cost of therapy of some biopharmaceuticals touching more than a hundred thousand dollars a year.
The cost of these drugs, however, is expected to be closely scrutinized by payers in the coming
years.

© IMARC®
Recombinant Proteins represented the biggest biopharmaceutical class in 2009, accounting for more
than 65% of the total global biopharmaceutical sales. Growth in this class is expected to be low in
most of the developed markets as a result of biosimilar entry and increasing cost containment
measures.
Monoclonal Antibodies are expected to be the biggest drivers of the biopharmaceutical market in
the next five years. Driven by a rich late stage pipeline and a strong uptake from both developed
and emerging market, Monoclonal Antibodies are expected to be worth more than US$ 79 Billion by
2015.
Imarc expects the top eight markets (US, Germany, Japan, France, Italy, Spain, UK and Canada) to
account for around 79% of the total global biopharmaceutical sales by 2015. This represents a
decline of 4% over their 2009 share.
The market share of emerging markets (Brazil, Russia, India, China, Mexico, Turkey and South
Korea) is likely to increase from less than 5% in 2009 to more than 8% by 2015.
Regions/Countries Covered
Global, US, Germany, Japan, France, Italy, Spain, United Kingdom, Canada, Russia, China, Australia, Turkey,
Mexico, South Korea, India, Brazil, Argentina and Indonesia.
Classes Covered for Each Region/Country
Recombinant Proteins, Insulin, Erythropoietins, Interferons, Colony Stimulating Factors, Immunoglobulins,
Recombinant Blood Factors, Growth Hormones, Recombinant Enzymes, Interleukins, Growth Factors,
Monoclonal Antibodies and Purified Proteins.
Key Features
Analysis of the key strengths, weaknesses, opportunities and threats faced by the global
biopharmaceutical market.
Exhaustive in-depth individual analysis for eighteen major developed and emerging markets.
2005 to 2009 trend analysis for the global and 18 selected biopharmaceutical markets.
2005 to 2009 trend analysis for individual biopharmaceutical classes for the global and 18 selected
biopharmaceutical markets.
2005 to 2009 trend analysis for the performance of top players for the global and 18 selected
biopharmaceutical markets.
2010-2015 sales forecast for the global and 18 selected biopharmaceutical markets.

© IMARC®
Table of Contents
1. Market Definitions & Research Methodology..............................................................................18
2. Analyst Briefing..............................................................................................................................21
3. Introduction to Biopharmaceuticals.............................................................................................26
4. Global Biopharmaceutical Market: Industry Analysis................................................................29
4.1 Strengths.....................................................................................................................................29
4.1.1 High Efficacy and Target Oriented Attack...........................................................................29
4.1.2 Strong Potential to Achieve Blockbuster Status..................................................................29
4.1.3 Limited Generic Threat........................................................................................................31
4.1.4 Approval Success Rates are Higher than Small Molecule Drugs.......................................34
4.2 Weaknesses ...............................................................................................................................34
4.2.1 Inconvenient Drug Delivery Coupled with Short Half Lives.................................................34
4.2.2 Second Line of Therapy......................................................................................................35
4.2.3 Huge Cost of Therapy.........................................................................................................36
4.2.4 High Incidence of Unfavorable Side Effects........................................................................37
4.3 Opportunities...............................................................................................................................37
4.3.1 Diseases with High Unmet Needs.......................................................................................37
4.3.2 Expanding the Patient Pool by Approval into Additional Indications...................................38
4.3.3 Emerging Markets ...............................................................................................................39
4.3.4 Increasing New Approvals and a Strong Pipeline...............................................................41
4.4 Threats........................................................................................................................................44
4.4.1 Biopharmaceutical Drug Development is a Very Risky Venture.........................................44
4.4.2 Biosimilars...........................................................................................................................45
4.4.3 Limited and Conditional Reimbursement............................................................................47
4.4.4 Uncertainties in the Economic Environment .......................................................................48
5. Global Biopharmaceutical Market: Industry Performance.........................................................50
5.1 Market Performance & Forecast.................................................................................................50
5.1.1 Current Performance (2005-2009)......................................................................................50
5.1.2 Market Forecasts (2010-2015)............................................................................................50
5.2 Market Segmentation by Region ................................................................................................52
5.2.1 Current Performance (2005-2009)......................................................................................52
5.3 Market Segmentation by Indication ............................................................................................56
5.4 Market Segmentation by Class...................................................................................................57
5.4.1 Recombinant Proteins.........................................................................................................59
5.4.1.1 Current Performance (2005-2009)..............................................................................59
5.4.1.2 Market Forecasts (2010-2015)....................................................................................61
5.4.2 Monoclonal Antibodies........................................................................................................63
5.4.2.2 Market Forecast (2010-2015)......................................................................................67
5.4.3 Purified Proteins..................................................................................................................70
5.4.3.2 Market Forecast (2010-2015)......................................................................................72
5.5 Competitive Landscape ..............................................................................................................73
5.5.1 Top Biopharmaceutical Players ..........................................................................................73
5.5.2 Top Biopharmaceutical Drugs.............................................................................................75
6. North America.................................................................................................................................77
6.1 US ...............................................................................................................................................77
6.1.1 Market Performance (2005-2009).......................................................................................77

© IMARC®
6.1.2 Market Segmentation by Class ...........................................................................................77
6.1.2.1 Recombinant Proteins.................................................................................................78
6.1.2.2 Monoclonal Antibodies ................................................................................................80
6.1.2.3 Purified Proteins..........................................................................................................82
6.1.3 Performance of Top Players ...............................................................................................83
6.2 Canada .......................................................................................................................................86
7. Latin America..................................................................................................................................94
7.1 Mexico.........................................................................................................................................94
7.1.2.3 Purified Proteins..........................................................................................................99
7.1.4 Market Forecasts (2010-2015)..........................................................................................101
7.2 Brazil.........................................................................................................................................102
7.2.1 Market Performance (2005-2009).....................................................................................102
7.2.2 Market Segmentation by Class .........................................................................................102
7.2.2.1 Recombinant Proteins...............................................................................................103
7.2.2.2 Monoclonal Antibodies ..............................................................................................105
7.2.2.3 Purified Proteins........................................................................................................107
7.2.3 Performance of Top Players .............................................................................................108
7.3 Argentina...................................................................................................................................111
8. Europe ...........................................................................................................................................119
8.1 Germany ...................................................................................................................................119
8.2 France.......................................................................................................................................128

© IMARC®
8.3 Italy ...........................................................................................................................................136
8.4 Spain.........................................................................................................................................145
8.5 UK .............................................................................................................................................154
8.6 Russia.......................................................................................................................................163
8.7 Turkey.......................................................................................................................................173
9. Asia Pacific ...................................................................................................................................182
9.1 Japan ........................................................................................................................................182
9.2 China.........................................................................................................................................192

© IMARC®
9.3 Australia....................................................................................................................................202
9.4 South Korea..............................................................................................................................210
9.5 India ..........................................................................................................................................219
9.6 Indonesia ..................................................................................................................................227

© IMARC®
List of Figures
Figure 2-1: Global Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009.........................25
Figure 3-1: Complexity of Biopharmaceuticals ...........................................................................................27
Figure 3-2: Sources of Biopharmaceuticals................................................................................................28
Figure 4-1: Global: Share of Biopharmaceuticals & Small Molecule Drugs Among the Top Ten Selling
Drugs (in %), 2000, 2009 & 2016................................................................................................................31
Figure 4-2: Using a Different Manufacturing Process Makes it Extremely Difficult for Biosimilars to be
Equivalent to Originator Products ...............................................................................................................32
Figure 4-3: Marked Differences Between Biosimilar and Branded Biopharmaceuticals When a Different
Production Process was Used ....................................................................................................................33
Figure 4-4: Transition Probabilities of Biopharmaceuticals & Small Molecule Drugs in Clinical Phases, (in
%)................................................................................................................................................................34
Figure 4-5: Comparison of the Average Annual Cost of Therapy Using Biopharmaceuticals and Small
Molecule Drugs, (in US$)............................................................................................................................36
Figure 4-6: Comparison of the Annual Cost of Therapy for Plaque Psoriasis Using Biopharmaceuticals
and Small Molecule Drugs, (in US$)...........................................................................................................36
Figure 4-7: Emerging Biopharmaceutical Market Forecast, (in Million US$), 2009 & 2015 .......................40
Figure 4-8: Developed Biopharmaceutical Market Forecast, (in Million US$), 2009 & 2015 .....................40
Figure 4-9: Total Number of New Biopharmaceuticals Approved by the FDA (in Numbers), 1982-2009 ..41
Figure 4-10: Breakup of Biopharmaceuticals and Small Molecule Drugs Receiving FDA Approval, (in %),
1993-2004 ...................................................................................................................................................43
Figure 4-11: Global: Breakup of Small Molecule Drugs and Biopharmaceuticals in the Total
Pharmaceutical Market & Phase III development, (%), 2009 .....................................................................43
Figure 4-12: A Comparison of the Costs Incurred While Developing Biopharmaceuticals and Small
Molecule Drugs, (in Million US$).................................................................................................................44
Figure 4-13: Research and Development Times Taken by Biopharmaceuticals to Reach the Market, (in
Months), 1982-89,1990-94,1995-99, 2000-04, 2005-09.............................................................................45
Figure 4-14: Comparison of the Research & Development Times for Biopharmaceuticals & Small
Molecule Drugs (in Months) ........................................................................................................................45
Figure 4-15: Germany: Volume Share of Branded and Biosimilar Products in the Erythropoietins Alpha
Market, (in %), September 2007 & April 2010 ............................................................................................47
Figure 4-16: Current Medicare Payer Coverage for Monoclonal Antibodies..............................................47
Figure 4-17: Performance of Biotech Stocks During the Financial Crisis, (in %), Jan 2008 to Dec 2008..49
Figure 5-1: Global: Biopharmaceutical Market, (in Million US$), 2005-2009..............................................50
Figure 5-2: Global: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015...............................52
Figure 5-3: Global: Biopharmaceutical Market: Sales Share by Country, (in %), 2009..............................53
Figure 5-4: Global: Biopharmaceutical Market Forecast: Sales Share by Country, (in %), 2015...............55
Figure 5-5: Global: Biopharmaceutical Market: Sales Share by Indication, (in %), 2009...........................56
Figure 5-6: Global: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009....................57
Figure 5-7: Global: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009 ........................57
Figure 5-8: Global: Biopharmaceutical Market Forecast: Sales by Class, (in Million US$), 2010-2015.....58
Figure 5-9: Global: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2010-2015.........58
Figure 5-10: Global: Recombinant Proteins Market, (in Million US$), 2005-2009......................................59
Figure 5-11: Global: Recombinant Proteins Market: Sales Share by Class, (in %), 2009 .........................61
Figure 5-12: Global: Recombinant Proteins Market Forecast, (in Million US$), 2010-2015.......................61
Figure 5-13: Global: Recombinant Proteins Market Forecast: Sales Share by Class, (in %), 2015 ..........63
Figure 5-14: Global: Monoclonal Antibodies Market, (in Million US$), 2005-2009.....................................64
Figure 5-15: Global: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009.........................65
Figure 5-16: Global: Monoclonal Antibodies Market Forecast, (in Million US$), 2010-2015......................69
Figure 5-17: Global: Monoclonal Antibodies Market Forecast: Sales Share by Class, (in %), 2015..........70
Figure 5-18: Global: Purified Proteins Market, (in Million US$), 2005-2009...............................................71
Figure 5-19: Global: Purified Proteins Market: Sales Share by Class, (in %), 2009...................................71
Figure 5-20: Global: Purified Proteins Market Forecast, (in Million US$), 2010-2015................................72
Figure 5-21: Global: Purified Proteins Market Forecast: Sales Share by Class, (in %), 2015 ...................73
Figure 5-22: Global Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009.......................75
Figure 6-1: US: Biopharmaceutical Market, (in Million US$), 2005-2009...................................................77

© IMARC®
Figure 6-2: US: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009.........................78
Figure 6-3: US: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009 .............................78
Figure 6-4: US: Recombinant Proteins Market, (in Million US$), 2005-2009 .............................................79
Figure 6-5: US: Recombinant Proteins Market: Sales Share by Class, (in %), 2009.................................80
Figure 6-6: US: Monoclonal Antibodies Market, (in Million US$), 2005-2009 ............................................80
Figure 6-7: US: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009 ................................81
Figure 6-8: US: Purified Proteins Market, (in Million US$), 2005-2009 ......................................................82
Figure 6-9: US: Purified Proteins Market: Sales Share by Class, (in %), 2009..........................................83
Figure 6-10: US: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009 ...........................84
Figure 6-11: US: Biopharmaceutical Market Forecast, (in Million US$), 2009-2015..................................85
Figure 6-12: US: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015......................85
Figure 6-13: Canada: Biopharmaceutical Market, (in Million US$), 2005-2009 .........................................86
Figure 6-14: Canada: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009 ...............86
Figure 6-15: Canada: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009....................87
Figure 6-16: Canada: Recombinant Proteins Market, (in Million US$), 2005-2009....................................87
Figure 6-17: Canada: Recombinant Proteins Market: Sales Share by Class, (in %), 2009 .......................89
Figure 6-18: Canada: Monoclonal Antibodies Market, (in Million US$), 2005-2009...................................89
Figure 6-19: Canada: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009 ......................90
Figure 6-20: Canada: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009....................92
Figure 6-21: Canada: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015 ..........................93
Figure 6-22: Canada: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015..............93
Figure 7-1: Mexico: Biopharmaceutical Market, (in Million US$), 2005-2009.............................................94
Figure 7-2: Mexico: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009...................95
Figure 7-3: Mexico: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009.......................95
Figure 7-4: Mexico: Recombinant Proteins Market, (in Million US$), 2005-2009.......................................95
Figure 7-5: Mexico: Recombinant Proteins Market: Sales Share by Class, (in %), 2009 ..........................97
Figure 7-6: Mexico: Monoclonal Antibodies Market, (in Million US$), 2005-2009......................................97
Figure 7-7: Mexico: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009..........................98
Figure 7-8: Mexico: Purified Proteins Market, (in Million US$), 2005-2009................................................99
Figure 7-9: Mexico: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009.....................100
Figure 7-10: Mexico: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015..........................101
Figure 7-11: Mexico: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015 .............101
Figure 7-12: Brazil: Biopharmaceutical Market, (in Million US$), 2005-2009...........................................102
Figure 7-13: Brazil: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009.................102
Figure 7-14: Brazil: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009 .....................103
Figure 7-15: Brazil: Recombinant Proteins Market, (in Million US$), 2005-2009 .....................................103
Figure 7-16: Brazil: Recombinant Proteins Market: Sales Share by Class, (in %), 2009.........................105
Figure 7-17: Brazil: Monoclonal Antibodies Market, (in Million US$), 2005-2009 ....................................105
Figure 7-18: Brazil: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009 ........................106
Figure 7-19: Brazil: Purified Proteins Market, (in Million US$), 2005-2009 ..............................................107
Figure 7-20: Brazil: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009 .....................109
Figure 7-21: Brazil: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015............................109
Figure 7-22: Brazil: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015................110
Figure 7-23: Argentina: Biopharmaceutical Market, (in Million US$), 2005-2009.....................................111
Figure 7-24: Argentina: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009...........111
Figure 7-25: Argentina: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009...............112
Figure 7-26: Argentina: Recombinant Proteins Market, (in Million US$), 2005-2009...............................112
Figure 7-27: Argentina: Recombinant Proteins Market: Sales Share by Class, (in %), 2009 ..................114
Figure 7-28: Argentina: Monoclonal Antibodies Market, (in Million US$), 2005-2009..............................114
Figure 7-29: Argentina: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009..................115
Figure 7-30: Argentina: Purified Proteins Market, (in Million US$), 2005-2009........................................116
Figure 7-31: Argentina: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009...............117
Figure 7-32: Argentina: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015 .....................118
Figure 7-33: Argentina: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015 .........118
Figure 8-1: Germany: Biopharmaceutical Market, (in Million US$), 2005-2009 .......................................119
Figure 8-2: Germany: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009 .............120
Figure 8-3: Germany: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009..................120
Figure 8-4: Germany: Recombinant Proteins Market, (in Million US$), 2005-2009 .................................120

© IMARC®
Figure 8-5: Germany: Recombinant Proteins Market: Sales Share by Class, (in %), 2009 .....................122
Figure 8-6: Germany: Monoclonal Antibodies Market, (in Million US$), 2005-2009.................................122
Figure 8-7: Germany: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009 ....................123
Figure 8-8: Germany: Purified Proteins Market, (in Million US$), 2005-2009 ..........................................124
Figure 8-9: Germany: Purified Proteins Market: Sales Share by Class, (in %), 2009 ..............................125
Figure 8-10: Germany: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009 ...............126
Figure 8-11: Germany: Biopharmaceutical Market Forecast, (in Million US$), 2009-2015 ......................127
Figure 8-12: Germany: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015..........127
Figure 8-13: France: Biopharmaceutical Market, (in Million US$), 2005-2009.........................................128
Figure 8-14: France: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009...............128
Figure 8-15: France: Biopharmaceutical Market: Sales Share By Class, (in %), 2005-2009...................129
Figure 8-16: France: Recombinant Proteins Market, (in Million US$), 2005-2009...................................129
Figure 8-17: France: Recombinant Proteins Market: Sales Share by Class, (in %), 2009.......................131
Figure 8-18: France: Monoclonal Antibodies Market, (in Million US$), 2005-2009 ..................................131
Figure 8-19: France: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009......................132
Figure 8-20: France: Purified Proteins Market, (in Million US$), 2005-2009............................................133
Figure 8-21: France: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009...................134
Figure 8-22: France: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015..........................135
Figure 8-23: France: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015 .............135
Figure 8-24: Italy: Biopharmaceutical Market, (in Million US$), 2005-2009 .............................................136
Figure 8-25: Italy: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009 ...................136
Figure 8-26: Italy: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009........................137
Figure 8-27: Italy: Recombinant Proteins Market, (in Million US$), 2005-2009........................................137
Figure 8-28: Italy: Recombinant Proteins Market: Sales Share by Class, (in %), 2009 ...........................139
Figure 8-29: Italy: Monoclonal Antibodies Market, (in Million US$), 2005-2009.......................................139
Figure 8-30: Italy: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009 ..........................140
Figure 8-31: Italy: Purified Proteins Market, (in Million US$), 2005-2009.................................................141
Figure 8-32: Italy: Biopharmaceutical Market: Sales Share of top players, (in %), 2009 .........................142
Figure 8-33: Italy: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015 ..............................143
Figure 8-34: Italy: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015..................144
Figure 8-35: Spain: Biopharmaceutical Market, (in Million US$), 2005-2009...........................................145
Figure 8-36: Spain: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009.................145
Figure 8-37: Spain: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009 .....................146
Figure 8-38: Spain: Recombinant Proteins Market, (in Million US$), 2005-2009.....................................146
Figure 8-39: Spain: Recombinant Proteins Market: Sales Share by Class, (in %), 2009.........................148
Figure 8-40: Spain: Monoclonal Antibodies Market, (in Million US$), 2005-2009 ....................................148
Figure 8-41: Spain: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009........................149
Figure 8-42: Spain: Purified Proteins Market, (in Million US$), 2005-2009..............................................150
Figure 8-43: Spain: Purified Proteins Market: Sales Share by Class, (in %), 2009..................................151
Figure 8-44: Spain: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009.....................152
Figure 8-45: Spain: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015............................153
Figure 8-46: Spain: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015 ...............153
Figure 8-47: UK: Biopharmaceutical Market, (in Million US$), 2005-2009...............................................154
Figure 8-48: UK: Biopharmaceutical Market, Sales by Class, (in Million US$), 2005-2009.....................155
Figure 8-49: UK: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009 .........................155
Figure 8-50: UK: Recombinant Proteins Market, (in Million US$), 2005-2009 .........................................156
Figure 8-51: UK: Recombinant Proteins Market: Sales Share by Class, (in %), 2009.............................157
Figure 8-52: UK: Monoclonal Antibodies Market, (in Million US$), 2005-2009 ........................................158
Figure 8-53: UK: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009 ............................159
Figure 8-54: UK: Purified Proteins Market, (in Million US$), 2005-2009 ..................................................159
Figure 8-55: UK: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009 .........................161
Figure 8-56: UK: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015................................162
Figure 8-57: UK: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015....................162
Figure 8-58: Russia: Biopharmaceutical Market, (in Million US$), 2005-2009.........................................163
Figure 8-59: Russia: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009...............164
Figure 8-60: Russia: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009 ...................164
Figure 8-61: Russia: Recombinant Proteins Market, (in Million US$), 2005-2009 ...................................165
Figure 8-62: Russia: Recombinant Proteins Market: Sales Share by Class, (in %), 2009.......................166

© IMARC®
Figure 8-63: Russia: Monoclonal Antibodies Market, (in Million US$), 2005-2009 ..................................167
Figure 8-64: Russia: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009 ......................168
Figure 8-65: Russia: Purified Proteins Market, (in Million US$), 2005-2009 ............................................168
Figure 8-66: Russia: Purified Proteins Market: Sales Share by Class, (in %), 2009................................169
Figure 8-67: Russia: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009 ...................171
Figure 8-68: Russia: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015..........................171
Figure 8-69: Russia: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015..............172
Figure 8-70: Turkey: Biopharmaceutical Market, (in Million US$), 2005-2009.........................................173
Figure 8-71: Turkey: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009...............174
Figure 8-72: Turkey: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009 ...................174
Figure 8-73: Turkey: Recombinant Proteins Market, (in Million US$), 2005-2009 ...................................175
Figure 8-74: Turkey: Recombinant Proteins Market: Sales Share by Class, (in %), 2009.......................176
Figure 8-75: Turkey: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009 ......................178
Figure 8-76: Turkey: Purified Proteins Market, (in Million US$), 2005-2009 ............................................178
Figure 8-77: Turkey: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009 ...................180
Figure 8-78: Turkey: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015..........................180
Figure 8-79: Turkey: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015..............181
Figure 9-1: Japan: Biopharmaceutical Market, (in Million US$), 2005-2009 ............................................183
Figure 9-2: Japan: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009 ..................183
Figure 9-3: Japan: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009.......................184
Figure 9-4: Japan: Recombinant Proteins Market, (in Million US$), 2005-2009 ......................................184
Figure 9-5: Japan: Recombinant Proteins Market: Sales Share by Class, (in %), 2009 ..........................186
Figure 9-6: Japan: Monoclonal Antibodies Market, (in Million US$), 2005-2009......................................186
Figure 9-7: Japan: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009 .........................187
Figure 9-8: Japan: Purified Proteins Market, (in Million US$), 2005-2009 ...............................................188
Figure 9-9: Japan: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009 ......................190
Figure 9-10: Japan: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015 ...........................191
Figure 9-11: Japan: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015...............191
Figure 9-12: China: Biopharmaceutical Market, (in Million US$), 2005-2009...........................................192
Figure 9-13: China: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009.................193
Figure 9-14: China: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009.....................193
Figure 9-15: China: Recombinant Proteins Market, (in Million US$), 2005-2009.....................................194
Figure 9-16: China: Recombinant Proteins Market: Sales Share by Class, (in %), 2009 ........................195
Figure 9-17: China: Monoclonal Antibodies Market, (in Million US$), 2005-2009....................................196
Figure 9-18: China: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009........................197
Figure 9-19: China: Purified Proteins Market, (in Million US$), 2005-2009..............................................197
Figure 9-20: China: Purified Proteins Market: Sales Share by Class, (in %), 2009..................................198
Figure 9-21: China: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009.....................200
Figure 9-22: China: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015 ...........................200
Figure 9-23: China: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015 ...............201
Figure 9-24: Australia: Biopharmaceutical Market, (in Million US$), 2005-2009......................................202
Figure 9-25: Australia: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009............202
Figure 9-26: Australia: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009 ................203
Figure 9-27: Australia: Recombinant Proteins Market, (in Million US$), 2005-2009 ................................203
Figure 9-28: Australia: Recombinant Proteins Market: Sales Share by Class, (in %), 2009....................205
Figure 9-29: Australia: Monoclonal Antibodies Market, (in Million US$), 2005-2009 ...............................205
Figure 9-30: Australia: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009...................206
Figure 9-31: Australia: Purified Proteins Market, (in Million US$), 2005-2009 .........................................207
Figure 9-32: Australia: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009 ................208
Figure 9-33: Australia: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015.......................209
Figure 9-34: Australia: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015...........209
Figure 9-35: South Korea: Biopharmaceutical Market, (in Million US$), 2005-2009................................210
Figure 9-36: South Korea: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009......211
Figure 9-37: South Korea: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009 ..........211
Figure 9-38: South Korea: Recombinant Proteins Market, (in Million US$), 2005-2009 ..........................212
Figure 9-39: South Korea: Recombinant Proteins Market: Sales Share by Class, (in %), 2009..............213
Figure 9-40: South Korea: Monoclonal Antibodies Market, (in Million US$), 2005-2009 .........................214
Figure 9-41: South Korea: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009.............215

© IMARC®
Figure 9-42: South Korea: Purified Proteins Market, (in Million US$), 2005-2009 ...................................215
Figure 9-43: South Korea: Purified Proteins Market: Sales Share by Class, (in %), 2009.......................216
Figure 9-44: South Korea: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009 ..........217
Figure 9-45: South Korea: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015.................218
Figure 9-46: South Korea: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015.....218
Figure 9-47: India: Biopharmaceutical Market, (in Million US$), 2005-2009 ............................................219
Figure 9-48: India: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009 ..................220
Figure 9-49: India: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009.......................220
Figure 9-50: India: Recombinant Proteins Market, (in Million US$), 2005-2009 ......................................221
Figure 9-51: India: Recombinant Proteins Market: Sales Share by Class, (in %), 2009 ..........................222
Figure 9-52: India: Monoclonal Antibodies Market, (in Million US$), 2005-2009......................................222
Figure 9-53: India: Purified Proteins Market, (in Million US$), 2005-2009 ...............................................223
Figure 9-54: India: Purified Proteins Market: Sales Share by Class, (in %), 2009 ...................................224
Figure 9-55: India: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009 ......................225
Figure 9-56: India: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015 .............................226
Figure 9-57: India: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015.................226
Figure 9-58: Indonesia: Biopharmaceutical Market, (in Million US$), 2005-2009 ....................................227
Figure 9-59: Indonesia: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009 ..........228
Figure 9-60: Indonesia: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009...............228
Figure 9-61: Indonesia: Recombinant Proteins Market, (in Million US$), 2005-2009...............................229
Figure 9-62: Indonesia: Recombinant Proteins Market: Sales Share by Class, (in %), 2009 ..................230
Figure 9-63: Indonesia: Monoclonal Antibodies Market, (in Million US$), 2005-2009..............................230
Figure 9-64: Indonesia: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009 .................231
Figure 9-65: Indonesia: Purified Proteins Market, (in Million US$), 2005-2009........................................232
Figure 9-66: Indonesia: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009...............233
Figure 9-67: Indonesia: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015 .....................234
Figure 9-68: Indonesia: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015.........234

© IMARC®
List of Tables
Table 1-1: Global: Biopharmaceutical Market: Definition & Segmentation.................................................19
Table 2-1: Global: Biopharmaceutical Market: SWOT Analysis .................................................................21
Table 2-2: Global: Recombinant Proteins Market Forecast: Sales by Class, (in Million US$), 2009 & 2015
....................................................................................................................................................................22
Table 2-3: Global: Monoclonal Antibodies Market Forecast: Sales by Class, (in Million US$), 2009 & 2015
....................................................................................................................................................................23
Table 2-4: Global: Purified Proteins Market Forecast: Sales by Class, (in Million US$), 2009 & 2015......23
Table 2-5: Global: Biopharmaceutical Market Forecast: Sales by Region, (in Million US$), 2009 & 2015 24
Table 3-1: Differences Between Small Molecule Drugs & Biopharmaceuticals .........................................26
Table 3-2: Complexity of Manufacturing Process Involved with Biopharmaceuticals & Small Molecule
Drugs...........................................................................................................................................................28
Table 4-1: Global: Top Ten Selling Drugs (Based on Origin), 2000 ...........................................................30
Table 4-2: Global: Top Ten Selling Drugs (Based on Origin), 2009 ...........................................................30
Table 4-3: Global: Top Ten Selling Drugs Forecast (Based on Origin), 2016............................................31
Table 4-4: Mode of Administration of Popular Biotech Drugs.....................................................................35
Table 4-5: FDA: Total Number of Biopharmaceutical Approvals in 2009...................................................42
Table 4-6: US and European Statistics of Branded Biopharmaceutical Products Facing Biosimilar Threat,
(in Million US$), 2009..................................................................................................................................46
Table 5-1: Global: Biopharmaceutical Market: Sales by Country (in Million US$), 2005-2009 ..................53
Table 5-2: Global: Biopharmaceutical Market Forecast: Sales by Country (in Million US$), 2010-2015 ...55
Table 5-3: Global: Biopharmaceutical Market: Sales by Indication, (in Billion US$), 2009 ........................56
Table 5-4: Global: Contribution of Various Classes to Total Biopharmaceutical Growth, (in Million US$),
2009-2015 ...................................................................................................................................................59
Table 5-5: Global: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009...............60
Table 5-6: Global: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009 ...................60
Table 5-7: Global: Recombinant Proteins Market Forecast: Sales by Class, (in %), 2010-2015...............62
Table 5-8: Global: Recombinant Proteins Market Forecast: Sales Share by Class, (in %), 2010-2015 ....62
Table 5-9: Global: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009 ..............64
Table 5-10: Global: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009.................64
Table 5-11: Global: Humanized Monoclonal Antibodies Market: Sales of Marketed Products, (in 000’
US$), 2009 ..................................................................................................................................................65
Table 5-12: Global: Chimeric Monoclonal Antibodies Market: Sales of Marketed Products, (in 000’ US$),
2009 ............................................................................................................................................................66
Table 5-13: Global: Fully Human Monoclonal Antibodies Market: Sales of Marketed Products, (in 000’
US$), 2009 ..................................................................................................................................................66
Table 5-14: Global: Murine Monoclonal Antibodies Market: Sales of Marketed Products, (in 000’ US$),
2009 ............................................................................................................................................................66
Table 5-15: Global: Murine Monoclonal Antibodies in Phase-III Development .........................................67
Table 5-16: Global: Chmeric Monoclonal Antibodies in Phase-III Development........................................68
Table 5-17: Global: Humanized Monoclonal Antibodies in Phase-III Development ...................................68
Table 5-18: Global: Fully Human Monoclonal Antibodies in Phase-III Development .................................68
Table 5-19: Global: Immunotoxins in Phase-III Development ...................................................................69
Table 5-20: Global: Monoclonal Antibodies Market Forecast: Sales by Class, (in Million US$), 2010-2015
....................................................................................................................................................................69
Table 5-21: Global: Monoclonal Antibodies Market Forecast: Sales Share by Class, (in %), 2010-2015..70
Table 5-22: Global: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009......................71
Table 5-23: Global: Purified Proteins Market: Sales Share by Class, (in %), 2005-2009 ..........................71
Table 5-24: Global: Purified Proteins Market Forecast: Sales by Class, (in Million US$), 2010-2015.......72
Table 5-25: Global: Purified Proteins Market Forecast: Sales Share by Class, (in %), 2010-2015 ...........72
Table 5-26: Global: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009 .........74
Table 5-27: Global: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2005-2009..............74
Table 5-28: Global: Biopharmaceutical Market; Sales Forecast of Top Biopharmaceuticals, (in Million
US$), 2009 & 2016......................................................................................................................................76
Table 6-1: US: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009 ....................79
Table 6-2: US: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009.........................79

© IMARC®
Table 6-3: US: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009....................81
Table 6-4: US: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009........................81
Table 6-5: US: Purified Proteins Market: Sales by Class, 2005-2009 ........................................................82
Table 6-6: US: Purified Proteins Market: Sales Share by Class, 2005-2009 .............................................82
Table 6-7: US: Biopharmaceutical Market: Sales of Top Players, (in US$), 2005-2009 ............................83
Table 6-8: US: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2005-2009 .....................84
Table 6-9: Canada: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009.............88
Table 6-10: Canada: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009 ...............88
Table 6-11: Canada: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009..........90
Table 6-12: Canada: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009 ..............90
Table 6-13: Canada: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009 .......91
Table 6-14: Canada: Biopharmaceutical Market: Sales Share of Top Players, (in %) 2005-2009.............91
Table 7-1: Mexico: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009..............96
Table 7-2: Mexico: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009 ..................96
Table 7-3: Mexico: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009 .............98
Table 7-4: Mexico: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009..................98
Table 7-5: Mexico: Purified Proteins Market: Sales by Class (in Million US$), 2005-2009........................99
Table 7-6: Mexico: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009 .......100
Table 7-7: Mexico: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2005-2009.............100
Table 7-8: Brazil: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009 ..............104
Table 7-9: Brazil: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009...................104
Table 7-10: Brazil: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009............106
Table 7-11: Brazil: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009................106
Table 7-12: Brazil: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009 .....................107
Table 7-13: Brazil: Purified Proteins Market: Sales Share by Class, (in %), 2005-2009..........................107
Table 7-14: Brazil: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009.........108
Table 7-15: Brazil: Biopharmaceutical Market: Sales Share of Top Players, (in %) 2005-2009 ..............108
Table 7-16: Argentina: Recombinant Proteins Market: Sales by Class, 2005-2009.................................113
Table 7-17: Argentina: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009 ..........113
Table 7-18: Argentina: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009 .....115
Table 7-19: Argentina: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009..........115
Table 7-20: Argentina: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009...............116
Table 7-21: Argentina: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009 ..116
Table 7-22: Argentina: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2005-2009.......117
Table 8-1: Germany: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009.........121
Table 8-2: Germany: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009.............121
Table 8-3: Germany: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009........123
Table 8-4: Germany: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009 ............123
Table 8-5: Germany: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009..................124
Table 8-6: Germany: Purified Proteins Market: Sales Share by Class, (in %), 2005-2009 ......................124
Table 8-7: Germany: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009.....125
Table 8-8: Germany: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2005-2009 .........126
Table 8-9: France: Recombinant Proteins Market: Sales by Class,(in Million US$), 2005-2009 .............130
Table 8-10: France: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009...............130
Table 8-11: France: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009 .........132
Table 8-12: France: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009..............132
Table 8-13: France: Purified Proteins Market: Sales by Class, 2005-2009..............................................133
Table 8-14: France: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009.......134
Table 8-15: France: Biopharmaceutical Market: Sales Share of Top Players, (in %) 2005-2009............134
Table 8-16: Italy: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009...............138
Table 8-17: Italy: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009 ...................138
Table 8-18: Italy: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009..............140
Table 8-19: Italy: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009 ..................140
Table 8-20: Italy: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009........................141
Table 8-21: Italy: Purified Proteins Market: Sales Share by Class, (in %), 2005-2009 ............................141
Table 8-22: Italy: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009 ...........142
Table 8-23: Italy: Biopharmaceutical Market: Sales Share of Top Players, (in %) 2005-2009.................142
Table 8-24: Spain: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009 ............147

© IMARC®
Table 8-25: Spain: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009.................147
Table 8-26: Spain: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009 ...........149
Table 8-27: Spain: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009................149
Table 8-28: Spain: Purified Proteins Market: Sales by Class, 2005-2009................................................150
Table 8-29: Spain: Purified Proteins Market: Sales Share by Class, 2005-2009 .....................................150
Table 8-30: Spain: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009.........151
Table 8-31: Spain: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2005-2009.............152
Table 8-32: UK: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009 ................156
Table 8-33: UK: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009.....................157
Table 8-34: UK: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009................158
Table 8-35: UK: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009....................158
Table 8-36: UK: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009 .........................160
Table 8-37: UK: Purified Proteins Market: Sales Share by Class, (in %), 2005-2009..............................160
Table 8-38: UK: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009.............161
Table 8-39: UK: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2005-2009 .................161
Table 8-40: Russia: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009 ..........165
Table 8-41: Russia: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009...............166
Table 8-42: Russia: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009..........167
Table 8-43: Russia: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009..............167
Table 8-44: Russia: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009 ...................169
Table 8-45: Russia: Purified Proteins Market: Sales Share by Class, (in %), 2005-2009........................169
Table 8-46: Russia: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009.......170
Table 8-47: Russia: Biopharmaceutical Market: Sales Share of Top Players, (in %) 2005-2009 ............170
Table 8-48: Turkey: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009 ..........175
Table 8-49: Turkey: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009...............176
Table 8-50: Turkey: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009..........177
Table 8-51: Turkey: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009..............177
Table 8-52: Turkey: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009 ...................179
Table 8-53: Turkey: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009.......179
Table 8-54: Turkey: Biopharmaceutical Market: Sales Share of Top Players, (in %) 2005-2009 ............179
Table 9-1: Japan: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009..............185
Table 9-2: Japan: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009..................185
Table 9-3: Japan: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009.............187
Table 9-4: Japan: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009 .................187
Table 9-5: Japan: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009.......................188
Table 9-6: Japan: Purified Proteins Market: Sales Share by Class, (in %), 2005-2009 ...........................188
Table 9-7: Japan: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009..........189
Table 9-8: Japan: Biopharmaceutical Market: Sales Share of Top Players, (in %) 2005-2009 ...............189
Table 9-9: China: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009..............194
Table 9-10: China: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009 ................195
Table 9-11: China: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009 ...........196
Table 9-12: China: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009................196
Table 9-13: China: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009.....................198
Table 9-14: China: Purified Proteins Market: Sales Share by Class, (in %), 2005-2009 .........................198
Table 9-15: China: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009 ........199
Table 9-16: China: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2005-2009.............199
Table 9-17: Australia: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009 .......204
Table 9-18: Australia: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009............204
Table 9-19: Australia: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009.......206
Table 9-20: Australia: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009...........206
Table 9-21: Australia: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009 ................207
Table 9-22: Australia: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009....207
Table 9-23: Australia: Biopharmaceutical Market: Sales Share of Top Players, (in %) 2005-2009 .........208
Table 9-24: South Korea: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009 .212
Table 9-25: South Korea: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009......213
Table 9-26: South Korea: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009.214
Table 9-27: South Korea: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009.....214
Table 9-28: South Korea: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009 ..........216

© IMARC®
Table 9-29: South Korea: Purified Proteins Market: Sales Share by Class, (in %), 2005-2009...............216
Table 9-30: South Korea: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009
..................................................................................................................................................................217
Table 9-31: South Korea: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2005-2009 ..217
Table 9-32: India: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009..............221
Table 9-33: India: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009..................221
Table 9-34: India: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009.............223
Table 9-35: India: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009.......................223
Table 9-36: India: Purified Proteins Market: Sales Share by Class, (in %), 2005-2009 ...........................223
Table 9-37: India: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009..........224
Table 9-38: India: Biopharmaceutical Market: Sales Share of Top Players, (in %) 2005-2009 ...............225
Table 9-39: Indonesia: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009......229
Table 9-40: Indonesia: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009 ..........229
Table 9-41: Indonesia: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009.....231
Table 9-42: Indonesia: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009 .........231
Table 9-43: Indonesia: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009...............232
Table 9-44: Indonesia: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009 ..233
Table 9-45: Indonesia: Biopharmaceutical Market: Sales Share of Top Players, (in %) 2005-2009........233

© IMARC®
Prices and Order Information
Single user license
PDF
Single user license
CD ROM
Single user license
Hard Copy
Multiple User License
All Formats
US$ 1,000 US$1,200 US$1,200 US$1,800
I would like to order the market Study “Global
Biopharmaceutical Market Report (2010-2015)”
Your Name:
Job Title:
Company:
Email Id:
Telephone Number:
Address:
Krishna Sharma
International Market Research Analysis and Consulting Group
91-11-43095788
Sales@imarcgroup.com
Kindly Complete Your Details
Contact IMARC Group

Global biopharmaceutical market report (2010 2015)

Recomendados

Recomendados

Mais conteúdo relacionado

Destaque

Destaque (8)

Último

Último (20)

Global biopharmaceutical market report (2010 2015)